Physician profile
Miriam Thomas
NPI 1578823464
$6,747.57
in general payments reported to CMS, 2019-2025
42 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $262 · 2021: $1,175 · 2022: $706 · 2023: $1,211 · 2024: $1,555 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,216.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $558.59 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $422.15 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $413.15 | 2019-2023 | |
| Lilly USA, LLC | $378.52 | 2020-2025 | Jardiance, Mounjaro, Lyumjev |
| Radius Health, INC. | $376.80 | 2020-2025 | Tymlos |
| Insulet Corporation | $311.23 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.06 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Medtronic, INC. | $259.29 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $229.71 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $220.30 | 2021-2025 | Synthroid |
| Dexcom, INC. | $208.49 | 2021-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $204.49 | 2019-2024 | Unithroid |
| Corcept Therapeutics | $176.30 | 2019-2023 | Korlym |
| Ascendis Pharma Endocrinology INC | $147.13 | 2023-2025 | Yorvipath |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $124.06 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $117.77 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $109.76 | 2023-2025 | Isturisa, Signifor Lar |
| Horizon Therapeutics Plc | $101.07 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $72.73 | 2020-2021 | |
| Madrigal Pharmaceuticals | $72.43 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $71.70 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $69.31 | 2022-2024 | Crysvita |
| Beta Bionics, INC. | $66.25 | 2024 | Ilet Bionic Pancreas |
| Acella Pharmaceuticals, LLC | $63.72 | 2023-2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $50.12 | 2019-2023 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $47.02 | 2025 | |
| Cequr Corporation | $42.18 | 2022-2025 | Cequr Simplicity |
| Inspire Medical Systems, INC. | $33.30 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $33.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.44 | 2019 | |
| Sandoz INC. | $25.09 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $25.01 | 2025 | Imcivree |
| Kyowa Kirin, INC. | $24.67 | 2025 | |
| Vivus LLC | $24.55 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.52 | 2025 | Strensiq |
| Chiesi USA, INC. | $22.96 | 2025 | Mycapssa |
| Astellas Pharma US INC | $22.91 | 2023 | Veozah |
| Echosens North America, INC. | $22.06 | 2024 | Fibroscan |
| Almatica Pharma LLC | $18.25 | 2025 | Teriparatide |
| Pfizer INC. | $17.41 | 2024 | |
| Amarin Pharma, INC. | $16.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.